GREENWICH THERAFECTIN POSITIVE PIVOTAL STUDY NEEDS REPLICATION
GREENWICH THERAFECTIN POSITIVE PIVOTAL STUDY NEEDS REPLICATION, FDA's Arthritis Advisory Committee decided after reviewing data from two pivotal and two supporting studies presented by the company Jan. 27. The advisory committee voted five to zero with two abstentions that the database for Greenwich Pharmaceuticals' Therafectin (amiprilose) does not support approval for treatment of rheumatoid arthritis. The committee agreed that pivotal study RA-9 showed the agent to be efficacious compared to placebo but felt that the other studies were inconclusive.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth